Sonex Health and The Institute of Advanced Ultrasound Guided Procedures today announced publication of six-month data demonstrating the safety and efficacy of ultrasound-guided carpal tunnel release (UGCTR) using UltraGuideCTR. The study represents the largest prospective evaluation of UGCTR to date.
The MISSION registry (Post-Market RegIStry of the Patient Experience when uSing UltraGuIdeCTR fOr Carpal TuNnel Release) is a prospective, multicenter study that is collecting real-world outcomes of patients suffering from CTS who are treated with a UGCTR procedure using Sonex Health’s commercially available device, UltraGuideCTR, endoscopic carpal tunnel release, or open carpal tunnel release in routine clinical practice in the United States. The goal of the MISSION registry is to compare symptom relief, functional outcomes, pain, quality of life, and patient satisfaction among the different procedural approaches to treat carpal tunnel syndrome.
The UGCTR data at six months includes 887 patients and 1,082 hands treated with UltraGuideCTR across 22 sites in the U.S. In this largest-ever prospective study of carpal tunnel release performed in the U.S., authors found that patients treated with UGCTR experienced rapid improvement in symptoms and function, and high patient satisfaction through six months. The study also demonstrates the ability to simultaneously treat both hands of patients suffering from bilateral CTS as part of a single procedure in routine clinical practice.
Sonex Health and The Institute of Advanced Ultrasound Guided Procedures today announced publication of six-month data demonstrating the safety and efficacy of ultrasound-guided carpal tunnel release (UGCTR) using UltraGuideCTR. The study represents the largest prospective evaluation of UGCTR to date.
The MISSION registry (Post-Market RegIStry...
Sonex Health and The Institute of Advanced Ultrasound Guided Procedures today announced publication of six-month data demonstrating the safety and efficacy of ultrasound-guided carpal tunnel release (UGCTR) using UltraGuideCTR. The study represents the largest prospective evaluation of UGCTR to date.
The MISSION registry (Post-Market RegIStry of the Patient Experience when uSing UltraGuIdeCTR fOr Carpal TuNnel Release) is a prospective, multicenter study that is collecting real-world outcomes of patients suffering from CTS who are treated with a UGCTR procedure using Sonex Health’s commercially available device, UltraGuideCTR, endoscopic carpal tunnel release, or open carpal tunnel release in routine clinical practice in the United States. The goal of the MISSION registry is to compare symptom relief, functional outcomes, pain, quality of life, and patient satisfaction among the different procedural approaches to treat carpal tunnel syndrome.
The UGCTR data at six months includes 887 patients and 1,082 hands treated with UltraGuideCTR across 22 sites in the U.S. In this largest-ever prospective study of carpal tunnel release performed in the U.S., authors found that patients treated with UGCTR experienced rapid improvement in symptoms and function, and high patient satisfaction through six months. The study also demonstrates the ability to simultaneously treat both hands of patients suffering from bilateral CTS as part of a single procedure in routine clinical practice.
Copy to clipboard 
